Thursday, November 30, 2006

Oncotype DX™ Contracts with Aetna

Aetna Health, one of the nation's largest health benefits companies, has formed an agreement with Genomic Health to establish pay rates for the use of Oncotype DX™. This agreement establishes payment rates for all of Aenta's plans for eligible members with early-stage breast cancer. Ultimately, this contract will cover an estimated 80 million people. Node-negative, early breast cancer refers to cancer that has not spread from the breast to other sites in the body, including lymph nodes under the arms. Although chemotherapy is recommended for many women with early-stage, node-negative breast cancer, the benefit of chemotherapy varies. Identifying in advance those women who are most likely to benefit from chemotherapy may allow for more individualized treatment. As a result, women who are unlikely to benefit from chemotherapy could avoid the unwanted side effects of treatment, while women who would benefit from chemotherapy could be treated accordingly. --Click the title of this post to read the full article from its source--

Labels: ,


Post a Comment

<< Home

/* WebRing Code */